It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Acetaminophen (APAP)-induced liver injury (AILI) is the most frequent cause of acute liver failure; but the underlying mechanisms still remain obscure. Macrophages and endoplasmic reticulum (ER) stress play an important role in the pathogenesis of AILI. Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a newly identified 18-kDa soluble protein, whose expression and secretion are stimulated by ER stress. To investigate the role of myeloid cell MANF in the pathogenesis of AILI, we assayed serum and liver samples from AILI model mice and patients with drug-induced liver injury (DILI). We demonstrated that the levels of MANF were elevated in patients with DILI and in mice with AILI. Moreover, myeloid-specific MANF knockout mice were generated and used. It was observed that a delayed liver recovery from myeloid-specific MANF gene knockout mice following APAP overdose compared to that from wild-type mice. MANF deficiency in myeloid cells resulted in increased infiltrating monocyte-derived macrophages (MoMFs) but reduced restorative Ly6Clow macrophages after APAP treatment. MANF supplementation increased restorative Ly6Clow macrophages and subsequently alleviated liver injury. Moreover, MANF could enhance IL-10 expression and phagocytosis in macrophages via p38 MAPK pathway. Altogether, MANF seems to be a critical immune modulator in promoting liver repair via reducing and reprogramming MoMFs. MANF perhaps promoted the phenotype conversion of pro-inflammatory MoMFs to pro-restorative Ly6Clow MoMFs via p38 MAPK pathway, particularly through enhancing IL-10 and phagocytosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Ningbo University, The Affiliated Hospital of Medical School, Ningbo, China (GRID:grid.203507.3) (ISNI:0000 0000 8950 5267); Ningbo University, School of Medicine, Ningbo, China (GRID:grid.203507.3) (ISNI:0000 0000 8950 5267)
2 Ningbo University, The Affiliated Hospital of Medical School, Ningbo, China (GRID:grid.203507.3) (ISNI:0000 0000 8950 5267); Anhui Medical University, School of Basic Medical Sciences, Hefei, China (GRID:grid.186775.a) (ISNI:0000 0000 9490 772X)
3 Anhui Medical University, School of Basic Medical Sciences, Hefei, China (GRID:grid.186775.a) (ISNI:0000 0000 9490 772X)
4 University of Science and Technology of China, The First Affiliated Hospital, Division of Life Sciences and Medicine, Hefei, China (GRID:grid.59053.3a) (ISNI:0000000121679639)
5 Ningbo University, The Affiliated Hospital of Medical School, Ningbo, China (GRID:grid.203507.3) (ISNI:0000 0000 8950 5267)
6 the First Affiliated Hospital of Anhui Medical University, Department of Oncology, Hefei, China (GRID:grid.412679.f) (ISNI:0000 0004 1771 3402)